AR043487A1 - Heterociclos fusionados de pirimidina y usos de los mismos - Google Patents
Heterociclos fusionados de pirimidina y usos de los mismosInfo
- Publication number
- AR043487A1 AR043487A1 ARP040100701A ARP040100701A AR043487A1 AR 043487 A1 AR043487 A1 AR 043487A1 AR P040100701 A ARP040100701 A AR P040100701A AR P040100701 A ARP040100701 A AR P040100701A AR 043487 A1 AR043487 A1 AR 043487A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- independently selected
- alkyl
- alkynyl
- alkenyl
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 6
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 5
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 5
- 125000003107 substituted aryl group Chemical group 0.000 abstract 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 5
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos, composiciones farmacéuticas que los contienen y métodos de uso de los mismos. Estos nuevos compuestos proveen un tratamiento o profilaxis del cáncer. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula estructural (1) donde: A es C=O, CH2, o SO2; B representa alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, o heterociclo opcionalmente sustituido; D es O o N donde O es opcionalmente sustituido con un R8, donde N es opcionalmente sustituido con uno o más R8, y cuando n es 0 y m es 0, R8 se adjunta directamente a B; R1 y R2 en combinación forman un anillo heteroaromático fusionado de 5 miembros está opcionalmente sustituido con 1 o 2 sustituyentes, dicho anillo tiene al menos un átomo de N, O o S, pero no más de 2 átomos de O o 2 átomos de S o 1 átomo de O y un átomo de S; R3 se selecciona independientemente entre H, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido, cicloalquinilo opcionalmente sustituido, arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; R4 y R5 se seleccionan independientemente entre H o alquilo opcionalmente sustituido, o R4 y R5 en combinación forman un anillo de 3, 4, 5 o 6 miembros, el cual puede también ser opcionalmente sustituido; R6 y R7 se seleccionan independientemente entre H, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido, cicloalquinilo opcionalmente sustituido, heterociclo opcionalmente sustituido, arilo opcionalmente sustituido, o R6 y R7 en combinación forman un anillo de 3,4, 5 o 6 miembros, el cual también puede ser sustituido; R8 se selecciona independientemente entre H, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido, cicloalquinilo opcionalmente sustituido, arilo opcionalmente sustituido, o heterociclo opcionalmente sustituido; R9 se selecciona independientemente entre H, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido, cicloalquinilo opcionalmente sustituido, arilo opcionalmente sustituido, o heterociclo opcionalmente sustituido.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0300627A SE0300627D0 (sv) | 2003-03-07 | 2003-03-07 | Novel fused heterocycles and uses therof |
SE0301138A SE0301138D0 (sv) | 2003-04-15 | 2003-04-15 | Novel fused heterocycles and uses thereof |
SE0301697A SE0301697D0 (sv) | 2003-06-10 | 2003-06-10 | Novel fused heterocycles and uses thereof |
SE0302826A SE0302826D0 (sv) | 2003-10-24 | 2003-10-24 | Novel fused heterocycles and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AR043487A1 true AR043487A1 (es) | 2005-08-03 |
Family
ID=32966643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040100701A AR043487A1 (es) | 2003-03-07 | 2004-03-05 | Heterociclos fusionados de pirimidina y usos de los mismos |
Country Status (25)
Country | Link |
---|---|
US (1) | US20060270689A1 (es) |
EP (1) | EP1601673B1 (es) |
JP (2) | JP3947758B2 (es) |
KR (1) | KR20050107784A (es) |
AR (1) | AR043487A1 (es) |
AT (1) | ATE433448T1 (es) |
AU (1) | AU2004218080B2 (es) |
BR (1) | BRPI0408150A (es) |
CA (1) | CA2518224C (es) |
CY (1) | CY1109300T1 (es) |
DE (1) | DE602004021477D1 (es) |
DK (1) | DK1601673T3 (es) |
ES (1) | ES2326647T3 (es) |
HK (1) | HK1084390A1 (es) |
IS (1) | IS8036A (es) |
MX (1) | MXPA05009577A (es) |
MY (1) | MY141583A (es) |
NO (1) | NO20054340L (es) |
NZ (1) | NZ542227A (es) |
PL (1) | PL1601673T3 (es) |
PT (1) | PT1601673E (es) |
SI (1) | SI1601673T1 (es) |
TW (1) | TW200510427A (es) |
UA (1) | UA81470C2 (es) |
WO (1) | WO2004078758A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0309892A2 (pt) | 2002-05-09 | 2011-04-05 | Cytokinetics Inc | composto, composição, métodos para modular a atividade da cinesina de ksp, para inibir a ksp, e para o tratamento de uma doença proliferativa celular, e, uso de um composto |
WO2006018628A1 (en) * | 2003-03-07 | 2006-02-23 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer |
WO2004087053A2 (en) * | 2003-03-25 | 2004-10-14 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
US7022850B2 (en) | 2003-05-22 | 2006-04-04 | Bristol-Myers Squibb Co. | Bicyclicpyrimidones and their use to treat diseases |
CA2575188A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer |
DE602005017283D1 (de) * | 2004-08-18 | 2009-12-03 | Astrazeneca Ab | Ausgewählte kondensierte heterocyclen und deren anwendung |
EP1856128A4 (en) * | 2005-01-19 | 2009-12-23 | Merck & Co Inc | MITOTIC INHIBITORS OF KINESIN |
DE102005011822A1 (de) * | 2005-03-15 | 2006-09-21 | Merck Patent Gmbh | Phthalazinone |
DE102005027168A1 (de) | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Tetrahydrochinoline |
KR101565971B1 (ko) * | 2007-06-21 | 2015-11-05 | 뉴로내슨트, 아이엔씨. | 이소티아졸로피리미디논을 사용하는 신경 발생을 자극하고 신경 변성을 억제하는 방법 및 조성물 |
WO2009001214A2 (en) * | 2007-06-28 | 2008-12-31 | Pfizer Products Inc. | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists |
CN114478429B (zh) * | 2020-11-13 | 2023-11-17 | 中国科学院大连化学物理研究所 | 一种3-烷硫基异噻唑衍生物及其合成方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US7230000B1 (en) * | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
CZ20031910A3 (cs) * | 2000-12-11 | 2003-12-17 | Tularik Inc. | Sloučenina s antagonistickými účinky na CXCR3 a farmaceutický postředek |
US6809102B2 (en) * | 2001-03-29 | 2004-10-26 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
AU2002363429B2 (en) * | 2001-11-07 | 2008-05-08 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
AU2002346471A1 (en) * | 2001-11-20 | 2003-06-10 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
DE60222302T2 (de) * | 2001-12-06 | 2008-05-29 | Merck & Co., Inc. | Inhibitoren von mitotischem kinesin |
WO2003049679A2 (en) * | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
AU2002363960B2 (en) * | 2001-12-06 | 2008-07-10 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
WO2003050122A2 (en) * | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
CA2468266A1 (en) * | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Substituted bicyclic pyrimidinones as a mitotic kinesin ksp inhibitors |
CN100381437C (zh) * | 2002-04-17 | 2008-04-16 | 赛特凯恩蒂克公司 | 化合物、组合物和方法 |
BR0309892A2 (pt) * | 2002-05-09 | 2011-04-05 | Cytokinetics Inc | composto, composição, métodos para modular a atividade da cinesina de ksp, para inibir a ksp, e para o tratamento de uma doença proliferativa celular, e, uso de um composto |
JP2005530785A (ja) * | 2002-05-09 | 2005-10-13 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、及び方法 |
US7038048B2 (en) * | 2002-05-23 | 2006-05-02 | Cytokinetics, Inc. | 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use |
JP2005533119A (ja) * | 2002-07-17 | 2005-11-04 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、及び方法 |
US7022850B2 (en) * | 2003-05-22 | 2006-04-04 | Bristol-Myers Squibb Co. | Bicyclicpyrimidones and their use to treat diseases |
US7345046B2 (en) * | 2003-05-30 | 2008-03-18 | Chiron Corporation | Heteroaryl-fused pyrimidinyl compounds as anticancer agents |
EP1636225B1 (en) * | 2003-06-20 | 2010-02-24 | Novartis Vaccines and Diagnostics, Inc. | Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents |
US20050165089A1 (en) * | 2003-10-06 | 2005-07-28 | Gustave Bergnes | Compounds, compositions and methods |
EP1680420A4 (en) * | 2003-11-07 | 2008-09-24 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
US20050158320A1 (en) * | 2003-11-12 | 2005-07-21 | Nichols M. J. | Combinations for the treatment of proliferative diseases |
US7501416B2 (en) * | 2004-02-06 | 2009-03-10 | Bristol-Myers Squibb Company | Quinoxaline compounds and methods of using them |
WO2005100357A1 (en) * | 2004-04-06 | 2005-10-27 | Chiron Corporation | Mitotic kinesin inhibitors |
KR20070072598A (ko) * | 2004-10-19 | 2007-07-04 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 인돌 및 벤지미다졸 유도체 |
-
2004
- 2004-03-04 DK DK04717339T patent/DK1601673T3/da active
- 2004-03-04 BR BRPI0408150-1A patent/BRPI0408150A/pt not_active IP Right Cessation
- 2004-03-04 MY MYPI20040755A patent/MY141583A/en unknown
- 2004-03-04 JP JP2006507939A patent/JP3947758B2/ja not_active Expired - Fee Related
- 2004-03-04 CA CA2518224A patent/CA2518224C/en not_active Expired - Fee Related
- 2004-03-04 EP EP04717339A patent/EP1601673B1/en not_active Expired - Lifetime
- 2004-03-04 AT AT04717339T patent/ATE433448T1/de active
- 2004-03-04 PT PT04717339T patent/PT1601673E/pt unknown
- 2004-03-04 ES ES04717339T patent/ES2326647T3/es not_active Expired - Lifetime
- 2004-03-04 WO PCT/SE2004/000304 patent/WO2004078758A1/en active Application Filing
- 2004-03-04 DE DE602004021477T patent/DE602004021477D1/de not_active Expired - Lifetime
- 2004-03-04 PL PL04717339T patent/PL1601673T3/pl unknown
- 2004-03-04 NZ NZ542227A patent/NZ542227A/en not_active IP Right Cessation
- 2004-03-04 MX MXPA05009577A patent/MXPA05009577A/es active IP Right Grant
- 2004-03-04 AU AU2004218080A patent/AU2004218080B2/en not_active Ceased
- 2004-03-04 SI SI200431186T patent/SI1601673T1/sl unknown
- 2004-03-04 US US10/548,138 patent/US20060270689A1/en not_active Abandoned
- 2004-03-04 KR KR1020057016722A patent/KR20050107784A/ko not_active Application Discontinuation
- 2004-03-05 AR ARP040100701A patent/AR043487A1/es not_active Application Discontinuation
- 2004-03-05 TW TW093105906A patent/TW200510427A/zh unknown
- 2004-04-03 UA UAA200509430A patent/UA81470C2/uk unknown
-
2005
- 2005-09-19 IS IS8036A patent/IS8036A/is unknown
- 2005-09-20 NO NO20054340A patent/NO20054340L/no unknown
-
2006
- 2006-04-18 HK HK06104612.4A patent/HK1084390A1/xx not_active IP Right Cessation
- 2006-07-25 JP JP2006201461A patent/JP2007063257A/ja active Pending
-
2009
- 2009-08-10 CY CY20091100845T patent/CY1109300T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP2006519853A (ja) | 2006-08-31 |
NO20054340L (no) | 2005-09-26 |
EP1601673A1 (en) | 2005-12-07 |
ATE433448T1 (de) | 2009-06-15 |
DK1601673T3 (da) | 2009-08-24 |
CY1109300T1 (el) | 2014-07-02 |
JP3947758B2 (ja) | 2007-07-25 |
BRPI0408150A (pt) | 2006-03-21 |
HK1084390A1 (en) | 2006-07-28 |
SI1601673T1 (sl) | 2009-10-31 |
ES2326647T3 (es) | 2009-10-16 |
CA2518224A1 (en) | 2004-09-16 |
JP2007063257A (ja) | 2007-03-15 |
PT1601673E (pt) | 2009-07-29 |
EP1601673B1 (en) | 2009-06-10 |
DE602004021477D1 (de) | 2009-07-23 |
AU2004218080A1 (en) | 2004-09-16 |
UA81470C2 (en) | 2008-01-10 |
KR20050107784A (ko) | 2005-11-15 |
US20060270689A1 (en) | 2006-11-30 |
AU2004218080B2 (en) | 2008-01-03 |
MY141583A (en) | 2010-05-14 |
WO2004078758A1 (en) | 2004-09-16 |
CA2518224C (en) | 2010-06-15 |
NZ542227A (en) | 2008-12-24 |
IS8036A (is) | 2005-09-19 |
TW200510427A (en) | 2005-03-16 |
MXPA05009577A (es) | 2005-12-12 |
PL1601673T3 (pl) | 2009-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20220567A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
AR088449A1 (es) | Benzilindazoles sustituidos | |
PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
AR036093A1 (es) | Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios | |
YU48390B (sh) | Novi derivati 2-anilinopirimidina, postupak za njihovo dobijanje i sredstva za uništavanje štetočina, koja sadrže ove derivate | |
AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
AR077818A1 (es) | Composiciones pesticidas | |
AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
AR020165A1 (es) | Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos | |
AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
ECSP045369A (es) | Derivados de n-[fenil(piperidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica | |
AR095708A1 (es) | Indazoles sustituidos con diaminoheteroarilo | |
AR041395A1 (es) | Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla | |
AR043487A1 (es) | Heterociclos fusionados de pirimidina y usos de los mismos | |
CO5700768A2 (es) | Derivados de benzoxazina y sus usos | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR069814A1 (es) | Derivados de 4 amino-pirimidina, proceso de preparacion y composiciones farmaceuticas que los contienen | |
AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure | ||
FA | Abandonment or withdrawal | ||
FB | Suspension of granting procedure |